CPD Module 4: The COMPASS Trial Question Title * 1. Please enter your contact information: Name: Organisation: Position: Email: Phone Number: OK Question Title * 2. Which of the following statements is true? All patients studied in the trial had acute coronary syndrome 90% of the patients enrolled in the COMPASS trial had peripheral artery disease The trial was stopped after 23 months (on average) due to safety concerns The vascular dose of rivaroxaban has been approved for use by SIGN All of the above None of the above OK Question Title * 3. What reduction in stroke was observed in the COMPASS study for patients receiving the vascular dose of rivaroxaban? 30% 32% 38% 42% 46% 58% OK Question Title * 4. What dose of rivaroxaban produced the significant effects on MACE and mortality in COMPASS? Rivaroxaban 2.5mg OD Rivaroxaban 2.5mg BID Rivaroxaban 5mg OD Rivaroxaban 5mg BID Rivaroxaban 2.5mg OD plus aspirin Rivaroxaban 2.5mg BID plus aspirin Rivaroxaban 5mg OD plus aspirin Rivaroxaban 5mg BID plus aspirin OK Question Title * 5. What reduction in mortality was seen in patients receiving the vascular dose of rivaroxaban? 1/4 1/5 1/8 1/10 1/20 OK Question Title * 6. Which patient group benefited the most from the vascular dose of rivaroxaban in the COMPASS trial? Those with reduced heart function Those with reduced renal function Those with diabetes Those with widespread atheroma OK Question Title * 7. True or false, the vascular dose of rivaroxaban has both a European and US marketing authorisation? True False OK DONE